P11-03. Mucosal trafficking and differentiation of vaccine-elicited CD8+ T-lymphocytes
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
P11-03. Mucosal trafficking and differentiation of vaccine-elicited CD8+ T-lymphocytes ; volume:6 ; number:3 ; day:22 ; month:10 ; year:2009 ; pages:1 ; date:10.2009
Retrovirology ; 6, Heft 3 (22.10.2009), 1, 10.2009
- Creator
-
Kaufman, DR
- Contributor
-
Simmons, NL
Barouch, DH
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-6-S3-P148
- URN
-
urn:nbn:de:1111-2016080711798
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kaufman, DR
- Simmons, NL
- Barouch, DH
- SpringerLink (Online service)
Other Objects (12)
Control of mucosal virus infection by influenza nucleoprotein-specific CD8+cytotoxic T lymphocytes
Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
A molecular signature of lung-resident CD8+ T cells elicited by subunit vaccination
Hepatic stellate cells induce gut tropism of CD8+ T lymphocytes
Regulatory role of CD8+T lymphocytes in bone marrow eosinophilopoiesis
CD8+ T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis
TIPE polarity proteins are required for mucosal deployment of T lymphocytes and mucosal defense against bacterial infection
Optimization of the immune responses elicited following delivery of vaccine antigens by the mucosal route
Ex Vivo Apoptosis in CD8+ Lymphocytes Predicts Rectal Cancer Patient Outcome
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma
Deciphering the complexities of mucosal innate lymphocytes: guardians and potential therapeutic targets
Control of mucosal virus infection by influenza nucleoprotein-specific CD8+cytotoxic T lymphocytes
Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
A molecular signature of lung-resident CD8+ T cells elicited by subunit vaccination
Hepatic stellate cells induce gut tropism of CD8+ T lymphocytes
Regulatory role of CD8+T lymphocytes in bone marrow eosinophilopoiesis
CD8+ T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis
TIPE polarity proteins are required for mucosal deployment of T lymphocytes and mucosal defense against bacterial infection
Optimization of the immune responses elicited following delivery of vaccine antigens by the mucosal route
Ex Vivo Apoptosis in CD8+ Lymphocytes Predicts Rectal Cancer Patient Outcome
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma
Deciphering the complexities of mucosal innate lymphocytes: guardians and potential therapeutic targets
Control of mucosal virus infection by influenza nucleoprotein-specific CD8+cytotoxic T lymphocytes
Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
A molecular signature of lung-resident CD8+ T cells elicited by subunit vaccination
Hepatic stellate cells induce gut tropism of CD8+ T lymphocytes
Regulatory role of CD8+T lymphocytes in bone marrow eosinophilopoiesis
CD8+ T lymphocytes in bronchoalveolar lavage in idiopathic pulmonary fibrosis
TIPE polarity proteins are required for mucosal deployment of T lymphocytes and mucosal defense against bacterial infection
Optimization of the immune responses elicited following delivery of vaccine antigens by the mucosal route
Ex Vivo Apoptosis in CD8+ Lymphocytes Predicts Rectal Cancer Patient Outcome
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma